Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Phase Ib Trial To Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of Filociclovir (MBX-400, Cyclopropavir) in Healthy Volunteers.

Rouphael NG, Hurwitz SJ, Hart M, Beck A, Anderson EJ, Deye G, Osborn B, Cai SY, Focht C, Amegashie C, Bowlin TL, Brooks J, Mulligan MJ.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00717-19. doi: 10.1128/AAC.00717-19. Print 2019 Sep.

PMID:
31285228
2.

Visualization of the Cellular Uptake and Trafficking of DNA Origami Nanostructures in Cancer Cells.

Wang P, Rahman MA, Zhao Z, Weiss K, Zhang C, Chen Z, Hurwitz SJ, Chen ZG, Shin DM, Ke Y.

J Am Chem Soc. 2018 Feb 21;140(7):2478-2484. doi: 10.1021/jacs.7b09024. Epub 2018 Feb 12.

PMID:
29406750
3.

Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors.

Gavegnano C, Brehm JH, Dupuy FP, Talla A, Ribeiro SP, Kulpa DA, Cameron C, Santos S, Hurwitz SJ, Marconi VC, Routy JP, Sabbagh L, Schinazi RF, Sékaly RP.

PLoS Pathog. 2017 Dec 21;13(12):e1006740. doi: 10.1371/journal.ppat.1006740. eCollection 2017 Dec.

4.

Systemic Delivery of Bc12-Targeting siRNA by DNA Nanoparticles Suppresses Cancer Cell Growth.

Rahman MA, Wang P, Zhao Z, Wang D, Nannapaneni S, Zhang C, Chen Z, Griffith CC, Hurwitz SJ, Chen ZG, Ke Y, Shin DM.

Angew Chem Int Ed Engl. 2017 Dec 11;56(50):16023-16027. doi: 10.1002/anie.201709485. Epub 2017 Nov 15.

PMID:
29076273
5.

6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.

Lin R, Elf S, Shan C, Kang HB, Ji Q, Zhou L, Hitosugi T, Zhang L, Zhang S, Seo JH, Xie J, Tucker M, Gu TL, Sudderth J, Jiang L, Mitsche M, DeBerardinis RJ, Wu S, Li Y, Mao H, Chen PR, Wang D, Chen GZ, Hurwitz SJ, Lonial S, Arellano ML, Khoury HJ, Khuri FR, Lee BH, Lei Q, Brat DJ, Ye K, Boggon TJ, He C, Kang S, Fan J, Chen J.

Nat Cell Biol. 2015 Nov;17(11):1484-96. doi: 10.1038/ncb3255. Epub 2015 Oct 19. Review.

6.

Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.

Saba NF, Hurwitz SJ, Magliocca K, Kim S, Owonikoko TK, Harvey D, Ramalingam SS, Chen Z, Rogerio J, Mendel J, Kono SA, Lewis C, Chen AY, Higgins K, El-Deiry M, Wadsworth T, Beitler JJ, Shin DM, Sun SY, Khuri FR.

Cancer. 2014 Dec 15;120(24):3940-51. doi: 10.1002/cncr.28965. Epub 2014 Aug 7.

7.

Randomized, double-blind, multicenter safety and efficacy study of rifalazil compared with azithromycin for treatment of uncomplicated genital Chlamydia trachomatis infection in women.

Geisler WM, Pascual ML, Mathew J, Koltun WD, Morgan F, Batteiger BE, Mayes A, Tao S, Hurwitz SJ, Sayada C, Schinazi RF.

Antimicrob Agents Chemother. 2014 Jul;58(7):4014-9. doi: 10.1128/AAC.02521-14. Epub 2014 May 5.

8.

Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics.

North TW, Villalobos A, Hurwitz SJ, Deere JD, Higgins J, Chatterjee P, Tao S, Kauffman RC, Luciw PA, Kohler JJ, Schinazi RF.

Antimicrob Agents Chemother. 2014 Jul;58(7):3927-33. doi: 10.1128/AAC.02522-14. Epub 2014 Apr 28.

9.

Approaches to hepatitis C treatment and cure using NS5A inhibitors.

Kohler JJ, Nettles JH, Amblard F, Hurwitz SJ, Bassit L, Stanton RA, Ehteshami M, Schinazi RF.

Infect Drug Resist. 2014 Mar 5;7:41-56. doi: 10.2147/IDR.S36247. eCollection 2014. Review.

10.

Prodrug strategies for improved efficacy of nucleoside antiviral inhibitors.

Hurwitz SJ, Schinazi RF.

Curr Opin HIV AIDS. 2013 Nov;8(6):556-64. doi: 10.1097/COH.0000000000000007. Review.

PMID:
24100876
11.

Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.

Saba NF, Hurwitz SJ, Kono SA, Yang CS, Zhao Y, Chen Z, Sica G, Müller S, Moreno-Williams R, Lewis M, Grist W, Chen AY, Moore CE, Owonikoko TK, Ramalingam S, Beitler JJ, Nannapaneni S, Shin HJ, Grandis JR, Khuri FR, Chen ZG, Shin DM.

Cancer Prev Res (Phila). 2014 Mar;7(3):283-91. doi: 10.1158/1940-6207.CAPR-13-0215. Epub 2013 Oct 3.

12.

Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors.

Hurwitz SJ, Schinazi RF.

Drug Discov Today Technol. 2012 Fall;9(3):e183-e193.

13.

Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages.

Gavegnano C, Detorio MA, Bassit L, Hurwitz SJ, North TW, Schinazi RF.

Antimicrob Agents Chemother. 2013 Mar;57(3):1262-9. doi: 10.1128/AAC.02012-12. Epub 2012 Dec 21.

14.

Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV.

Shikuma CM, Nakamoto B, Shiramizu B, Liang CY, DeGruttola V, Bennett K, Paul R, Kallianpur K, Chow D, Gavegnano C, Hurwitz SJ, Schinazi RF, Valcour VG.

Antivir Ther. 2012;17(7):1233-42. doi: 10.3851/IMP2411. Epub 2012 Sep 28.

15.

Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.

Hurwitz SJ, Zhang H, Yun S, Batuwangala TD, Steward M, Holmes SD, Rycroft D, Pan L, Tighiouart M, Shin HJ, Koenig L, Wang Y, Chen ZG, Shin DM.

Cancer Chemother Pharmacol. 2012 Mar;69(3):577-90. doi: 10.1007/s00280-011-1713-x. Epub 2011 Sep 13.

PMID:
21913035
16.

In silico study supports the efficacy of a reduced dose regimen for stavudine.

Hurwitz SJ, Schinazi RF.

Antiviral Res. 2011 Nov;92(2):372-7. doi: 10.1016/j.antiviral.2011.08.004. Epub 2011 Aug 22.

17.

Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals.

Hurwitz SJ, Asif G, Fromentin E, Tharnish PM, Schinazi RF.

Antimicrob Agents Chemother. 2010 Mar;54(3):1248-55. doi: 10.1128/AAC.01209-09. Epub 2009 Dec 28.

18.

Simultaneous quantification of 9-(beta-D-1,3-dioxolan-4-yl)guanine, Amdoxovir and Zidovudine in human plasma by liquid chromatography-tandem mass spectrometric assay.

Fromentin E, Asif G, Obikhod A, Hurwitz SJ, Schinazi RF.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 1;877(29):3482-8. doi: 10.1016/j.jchromb.2009.08.030. Epub 2009 Aug 27.

19.

Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer.

Klass CM, Choe MS, Hurwitz SJ, Tighiouart M, Zhang X, Chen ZG, Shin DM.

Head Neck. 2009 Oct;31(10):1263-73. doi: 10.1002/hed.21103.

20.

Approaches for the development of antiviral compounds: the case of hepatitis C virus.

Schinazi RF, Coats SJ, Bassit LC, Lennerstrand J, Nettles JH, Hurwitz SJ.

Handb Exp Pharmacol. 2009;(189):25-51. doi: 10.1007/978-3-540-79086-0_2. Review.

PMID:
19048196
21.

Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model.

Hurwitz SJ, Asif G, Kivel NM, Schinazi RF.

Antimicrob Agents Chemother. 2008 Dec;52(12):4241-50. doi: 10.1128/AAC.00054-08. Epub 2008 Oct 6.

22.

Short communication cellular pharmacology of 9-(beta-D-1,3-dioxolan-4-yl) guanine and its lack of drug interactions with zidovudine in primary human lymphocytes.

Hernandez-Santiago BI, Obikhod A, Fromentin E, Hurwitz SJ, Schinazi RF.

Antivir Chem Chemother. 2007;18(6):343-6.

PMID:
18320938
23.

Development of a population simulation model for HIV monotherapy virological outcomes using lamivudine.

Hurwitz SJ, Asif G, Schinazi RF.

Antivir Chem Chemother. 2007;18(6):329-41.

PMID:
18320937
24.

Antiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection.

Menne S, Asif G, Narayanasamy J, Butler SD, George AL, Hurwitz SJ, Schinazi RF, Chu CK, Cote PJ, Gerin JL, Tennant BC.

Antimicrob Agents Chemother. 2007 Sep;51(9):3177-84. Epub 2007 Jul 2.

25.

Pharmacokinetics of the antiviral agent beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine in rhesus monkeys.

Asif G, Hurwitz SJ, Shi J, Hernandez-Santiago BI, Schinazi RF.

Antimicrob Agents Chemother. 2007 Aug;51(8):2877-82. Epub 2007 Jun 11.

26.

Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.

Asif G, Hurwitz SJ, Obikhod A, Delinsky D, Narayanasamy J, Chu CK, McClure HM, Schinazi RF.

Antimicrob Agents Chemother. 2007 Jul;51(7):2424-9. Epub 2007 May 7.

27.

Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses.

Schinazi RF, Hernandez-Santiago BI, Hurwitz SJ.

Antiviral Res. 2006 Sep;71(2-3):322-34. Epub 2006 Apr 18. Review. Erratum in: Antiviral Res. 2006 Dec;72(3):256.

PMID:
16716415
28.

The boron-neutron capture agent beta-D-5-o-carboranyl-2'-deoxyuridine accumulates preferentially in dividing brain tumor cells.

Moore C, Hernández-Santiago BI, Hurwitz SJ, Tan C, Wang C, Schinazi RF.

J Neurooncol. 2005 Sep;74(3):275-80.

PMID:
16132519
29.

Pharmacology and pharmacokinetics of the antiviral agent beta-D-2',3'-dideoxy-3'-oxa-5-fluorocytidine in cells and rhesus monkeys.

Hernandez-Santiago BI, Chen H, Asif G, Beltran T, Mao S, Hurwitz SJ, Grier J, McClure HM, Chu CK, Liotta DC, Schinazi RF.

Antimicrob Agents Chemother. 2005 Jul;49(7):2589-97.

30.
31.

Pharmacokinetics of the antiviral agent beta-L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine in rhesus monkeys.

Asif G, Hurwitz SJ, Gumina G, Chu CK, McClure HM, Schinazi RF.

Antimicrob Agents Chemother. 2005 Feb;49(2):560-4.

32.

Tissue disposition of 5-o-carboranyluracil--a novel agent for the boron neutron capture therapy of prostate cancer.

Schinazi RF, Hurwitz SJ, Liberman I, Glazkova Y, Mourier NS, Olson J, Keane T.

Nucleosides Nucleotides Nucleic Acids. 2004;23(1-2):291-306.

PMID:
15043155
34.

Antiviral activity and pharmacokinetics of 1-(2,3-dideoxy-2-fluoro-beta-L-glyceropent-2-enofuranosyl)cytosine.

Chen H, Pai SB, Hurwitz SJ, Chu CK, Glazkova Y, McClure HM, Feitelson M, Schinazi RF.

Antimicrob Agents Chemother. 2003 Jun;47(6):1922-8.

35.

Viral pharmacodynamic model for (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine (emtricitabine) in chronically infected woodchucks.

Hurwitz SJ, Tennant BC, Korba BE, Liberman I, Gerin JL, Schinazi RF.

Antivir Chem Chemother. 2002 May;13(3):165-76.

PMID:
12448689
36.
37.

Cellular pharmacology of the D- and L-enantiomers of beta-5-o-carboranyl-2'-deoxyuridine.

Hurwitz SJ, Ma L, Eleuteri A, Wright J, Moravek J, Schinazi RF.

Nucleosides Nucleotides Nucleic Acids. 2000 Mar;19(3):691-702.

PMID:
10843501
38.

Treatment of isografted 9L rat brain tumors with beta-5-o-carboranyl-2'-deoxyuridine neutron capture therapy.

Schinazi RF, Hurwitz SJ, Liberman I, Juodawlkis AS, Tharnish P, Shi J, Liotta DC, Coderre JA, Olson J.

Clin Cancer Res. 2000 Feb;6(2):725-30.

39.

Enantioselective synthesis and biological evaluation of 5-o-carboranyl pyrimidine nucleosides.

Mourier NS, Eleuteri A, Hurwitz SJ, Tharnish PM, Schinazi RF.

Bioorg Med Chem. 1999 Dec;7(12):2759-66.

PMID:
10658581
40.

Pharmacokinetics of the antiviral agent beta-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys.

Ma L, Hurwitz SJ, Shi J, Mcatee JJ, Liotta DC, McClure HM, Schinazi RF.

Antimicrob Agents Chemother. 1999 Feb;43(2):381-4.

41.

Clioquinol-zinc chelate: a candidate causative agent of subacute myelo-optic neuropathy.

Arbiser JL, Kraeft SK, van Leeuwen R, Hurwitz SJ, Selig M, Dickersin GR, Flint A, Byers HR, Chen LB.

Mol Med. 1998 Oct;4(10):665-70.

42.

Pharmacodynamics of (-)-beta-2',3'-dideoxy-3'-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans.

Hurwitz SJ, Tennant BC, Korba BE, Gerin JL, Schinazi RF.

Antimicrob Agents Chemother. 1998 Nov;42(11):2804-9. Erratum in: Antimicrob Agents Chemother 1998 Dec;42(12):3337.

43.

Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes.

Hurwitz SJ, Terashima M, Mizunuma N, Slapak CA.

Blood. 1997 May 15;89(10):3745-54.

PMID:
9160680
44.

Effect of BSO and etanidazole on neurofilament degradation in neonatal rat spinal cord cultures.

Palayoor ST, Bump EA, Saroff DM, Delfs JR, Geula C, Menton-Brennan L, Hurwitz SJ, Coleman CN, Stevenson MA.

Br J Cancer Suppl. 1996 Jul;27:S117-21.

45.

Phase I pharmacokinetic study of the hypoxic cell sensitizer etanidazole with carboplatin and cyclophosphamide in the treatment of advanced ovarian cancer.

Shulman LN, Buswell L, Goodman H, Muto M, Berkowitz R, Teicher B, Kusumoto T, Hurwitz SJ, Kalish LA, Coleman CN.

Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):545-8.

PMID:
8005814
46.

Modification of the aerobic cytotoxicity of etanidazole.

Palayoor ST, Bump EA, Malaker K, Langley RE, Saroff DM, Delfs JR, Hurwitz SJ, Coleman CN.

Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):289-93.

PMID:
8195021
47.

Pharmacodynamics of prolonged treatment with L,S-buthionine sulfoximine.

Malaker K, Hurwitz SJ, Bump EA, Griffith OW, Lai LL, Riese N, Coleman CN.

Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):407-12.

PMID:
7910818
48.
49.

Distribution of etanidazole into human brain tumors: implications for treating high grade gliomas.

Hurwitz SJ, Coleman CN, Riese N, Loeffler JS, Alexander E 3rd, Buswell L, Neben TY, Shargel L, Kramer RA.

Int J Radiat Oncol Biol Phys. 1992;22(3):573-6.

PMID:
1531216
50.

The effect of pH and concentration on the rates of kill of benzoic acid solutions against E. coli.

Hurwitz SJ, McCarthy TJ.

J Clin Pharm Ther. 1987 Apr;12(2):107-15.

PMID:
3294865

Supplemental Content

Loading ...
Support Center